Khiron Life Sciences expands cultivation area in Colombia
Khiron Life Sciences (TSXV: KHRN) announced it has notified the Colombian Ministry of Justice that it has expanded its cultivation area to 17.5 hectares of prime agricultural land near Ibague contiguous to the existing cultivation and production activities. The new site represents a 4-fold increase in the cultivation area and has an ideal climate profile, abundance of water, power, and skilled labour to scale cultivation and production. The area is located in a highly secure region of Colombia. The total site is estimated to be capable of producing 100,000 kilograms of dry flower for extraction and processing into medical formations compared to 8,000 kilograms at present.
This represents a twelve times increase in production. Site inspections for the final certification of the cultivation and production processes are currently being completed. Both high tetrahydrocannabinol content (THC) and cannabidiol (CBD) cannabis plants will be grown and KHRN expects to be one of the first companies to receive approvals and quota to commence commercial production (read full news release here).
KHRN is marching relentlessly toward generating revenue before the end of 2018. We believe KHRN’s market cap will approach and even exceed the valuations given to its Colombian-based competitors as investors realize KHRN is advancing steadily along the path laid out in its business plan. If this happens, KHRN shareholders will be richly rewarded.